TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Bladder Catheterization Strategies in Thoracic Surgery Patients With an Enhanced Recovery After Surgery (ERAS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing scheduled thoracic surgery at the study center~* Be of legal age~* Be eligible for the enhanced recovery after surgery (ERAS) protocol in effect in the department.~Exclusion Criteria:~* Non-intubated anesthesia with spontaneous ventilation (NIVATS)~* Already have an indwelling bladder catheter or suprapubic catheter or double J catheter or other urinary drainage device~* Urinary tract infection under treatment or bladder catheterization less than one month old~* Indication of per- or postoperative bladder catheterization for another reason (e.g. monitoring of diuresis in chronic renal failure)~* Known vesico-sphincter disorder with documented post-void residue~* Neurological bladder (spinal cord injury or stroke sequelae)~* Documented urinary incontinence~* Chronic renal failure with a glomerular filtration rate (GFR) \< 30 ml/min~* Contraindication to bladder catheterization (e.g. stenosis of the urethra)~* Be under legal protection or incapable of giving consent~* Failure to obtain written informed consent after a reflection period~* Not be affiliated to a French social security system or a beneficiary of such a system~* Long-term morphine drugs~* Pregnancy in progress or planned during the study period, Pregnant or nursing women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Systematic Intermittent Catheterization (SIC) (Type: EXPERIMENTAL): A bladder catheter will be placed in the operating room, at the end of the operation, in a patient still under general anesthesia. Once the urine has been drained and quantified, the bladder catheter will be removed before the patient is discharged and extubated.
- Bladder Scan Guided Catheterization (BSGC) (Type: ACTIVE_COMPARATOR): No systematic catheterization will be performed, the indication for catheterization will be guided by bladder-scan volume monitoring.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: PleuraSeal Pivotal Study (US)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective pulmonary lobectomy, segmental and/or wedge resection in one or more lobes via an open thoracotomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PleuraSeal Sealant Device (Type: EXPERIMENTAL): None
- Control (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed single, primary bronchogenic non-small cell lung cancer meeting the following subtypes:~  * Adenocarcinoma (no bronchioalveolar cell histology)~ * Squamous cell carcinoma~ * Large cell carcinoma~* Meeting the following staging criteria:~  * Stage IIB (T2, N1, M0, or T3, N0, M0)~ * Stage IIIA (T1-3, N2, M0 or T3, N1, M0)~ * Stage IIIB (Any T, N3, M0 or T4, Any N, M0)~* No more than 1 parenchymal lesion in the same lung or in both lungs~* No tumor involving the superior sulcus (e.g., Pancoast tumor)~* Patients must undergo evaluation by the involved thoracic surgeon, medical oncologist, and radiation oncologist prior to registration~* No evidence of metastatic disease~  * Biopsy or aspiration cytology required to confirm the benign diagnosis of CT or MRI abnormalities that potentially represent metastatic disease~ * Biopsy required if all noninvasive tests are indeterminant~PATIENT CHARACTERISTICS:~* Karnofsky performance status 70-100%~* Absolute granulocyte count ≥ 1,500/μL~* Platelet count ≥ 100,000/μL~* Bilirubin ≤ 3 times upper limit of normal (ULN)~* SGOT and SGPT ≤ 3 times ULN~* Creatinine clearance \> 50 mL/min~* No prior malignancy except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, ductal or lobular carcinoma in situ of the breast, or any other cancer from which the patient has been disease-free for 5 years~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective protection~* No significant hearing loss or patient unwilling to accept potential for further hearing loss~* No uncontrolled medical illness by appropriate medical therapy (e.g., myocardial infarction within the past 3 months or liver cirrhosis)~* No symptomatic peripheral neuropathy affecting activities of daily living~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or radiotherapy for lung cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Gemcitabine + Cisplatin (Type: EXPERIMENTAL): Surgical resection followed by (within 60 days) by chemotherapy (Gemcitabine at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle and Cisplatin at 75 mg/m2 IV over 1 hour on day 8 of a 21 day cycle) followed by radiation therapy (treated using linear accelerator with photon beam energy of 6-21 MV) upon completion of 3 cycles of chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Four or more American College of Rheumatology (ACR) criteria for the classification of SLE or 4 or more of the SLICE criteria~* Involvement of one or more of the following organ systems: renal, neurologic, hematologic, cardiac, pulmonary, gastrointestinal~* A lack of response to corticosteroids in moderate-to-high doses, and to either an equivalent degree of immunosuppression with azathioprine, methotrexate, cyclosporin, tacrolimus, belimumab, rituximab, mycophenolate mofetil, and/or appropriate other treatment~* Patients should be eligible for transplantation according to the BMT Policy Manual~Exclusion Criteria:~* Age less than 18 years and over 75 years~* Any risk of pregnancy~* Patients who are preterminal or moribund

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Nonmyeloablative Conditioning and BMT (Type: EXPERIMENTAL): Nonmyeloablative conditioning with rabbit antithymocyte globulin, cyclophosphamide, fludarabine, and total body irradiation. Allogeneic bone marrow transplant on Day 0. Graft versus host disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and tacrolimus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Eligibility will be determined in a stepped process:~1. All infants with a gestational age ≥ 36 weeks will be screened for study entry if they are admitted to the NICU with a diagnosis of fetal acidosis, perinatal asphyxia, neonatal depression or encephalopathy.~2. Infants will be eligible if:~   * They have a pH ≤ 7.0 or a base deficit ≥ 16m mEq/ L on umbilical cord or any postnatal sample within 1 hour of age.~  * If, during this interval, they have a pH between 7.01 and 7.15, a base deficit is between 10 and 15.9 mEq/L, or a blood gas is not available, AND they have an acute perinatal event AND either a 10-minute Apgar score ≤ 5 or assisted ventilation initiated at birth and continued for at least 10 minutes.~3. Once these criteria are met, eligible infants will have a standardized neurological examination performed by a certified physician examiner. Infants will be candidates for the study when encephalopathy or seizures are present. For this study, encephalopathy is defined as the presence of 1 or more signs in 3 of the following 6 categories:~   * Level of consciousness: lethargy, stupor or coma;~  * Spontaneous activity: decreased, absent;~  * Posture: distal flexion, decerebrate;~  * tone: hypotonia, flaccid or hypertonia, rigid;~  * Primitive reflexes: a) suck, weak, absent; b) Moro, incomplete, flaccid;~  * Autonomic nervous system: a) pupils: constricted, unequal, skew deviation or non reactive to light; b) heart rate: bradycardia, variable heart rate or c) respiration: periodic breathing, apnea.~Eligible infants from multiple births will be enrolled in the same arm of the study.~Exclusion Criteria:~* Inability to randomize by 6 hours of age~* Major congenital abnormality~* Major chromosomal abnormality (including Trisomy 21),~* Severe growth restriction (≤ 1800gm birth weight),~* Infant is moribund and will not receive any further aggressive treatment,~* Refusal of consent by parent~* Refusal of consent by attending neonatologist~* Infants with a core temperature \< 33.5°C for \> 1 hour at the time of screening by the research team would not be eligible for the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Hours
- Healthy Volunteers: f

Study Arms:
- 33.5°C for 72 hours (Type: ACTIVE_COMPARATOR): Target Temp: 33.5°C Duration: 72 hrs
- 33.5°C for 120 hours (Type: EXPERIMENTAL): Target Temp: 33.5°C Duration: 120 hrs
- 32.0°C for 72 hours (Type: EXPERIMENTAL): Target Temp: 32.0°C Duration: 72 hrs
- 32.0°C for 120 hours (Type: EXPERIMENTAL): Target Temp: 32.0°C Duration:120 hrs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* aged 18 years or more~* with RA according to ACR criteria~* presented with a disease flare after initial response to infliximab, with both response and flare being defined using the DAS28 score (EULAR criteria)~* received the standard Remicade® dosing schedule per the EU label (3 mg/kg at Weeks 0, 2, 6, \[and 14\])~* an initial response documented by moderate or good DAS28 improvement (EULAR criteria) from Week 0 to Week 6 or 14.~Exclusion Criteria:~* a female who is, or intends to become, pregnant during or within 6 months of the end of the study, is nursing or not using adequate contraceptive measures~* has not observed the designated periods for concomitant medications~* used any investigational medical product within 30 days prior to Baseline~* any clinically significant deviation from normal in the physical examination or chest X-ray that in the investigator's judgment, may interfere with the study evaluation or affect subject safety~* rheumatic disease other than RA or has any systemic inflammatory condition with signs and symptoms that might confound the evaluations of safety and toxicity~* allergic reaction/sensitivity to the study drug or its excipients that requires corticosteroid pre-infusion medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Increased Frequency (Type: EXPERIMENTAL): Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks
- Increased Dose (Type: EXPERIMENTAL): 3 mg/kg infliximab + 1 extra vial (100 mg) infliximab, every 8 weeks
- Control (Type: ACTIVE_COMPARATOR): Continuation of infliximab 3 mg/kg every 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnose is histologically or cytologically proven (NSCLC,SCLC), malignant mesothelioma (histologically)~* at least 4 cycles of cisplatin are planned~* adequate renal function (creatinine clearance as calculated by Cockroft-Gault method \> 60 ml/min)~* Karnofsky performance score \> 60 %~* written informed consent~* patient must be able to comply with study measurements i.e. hospital visits for EMG and QoL assessments~* age ≥ 18 years~Exclusion Criteria:~* patients with pre-existing neuropathy~* patients not willing to stop earlier prescribed NAC~* patients not willing to stop vitamins E and A above daily advisory dosage~* uncontrolled metastasis in the central or peripheral nervous system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): N-Acetylcysteine
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Factors Influencing Quality of Bowel Cleansing for Colonoscopy in Patients With Colorectal Cancer Surgery; Prospective Observational Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 20~* patients who underwent colorectal cancer surgery~* patients who underwent follow-up colonoscopy as a conventional medical procedures~Exclusion Criteria:~* age \< 20~* patients who have ileus or bowel obstruction~* patients in pregnant status~* Patients who did not consent to research

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Colonoscopy (Type: None): patients undergoing colonoscopy after colorectal cancer surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: A patient's study eye must meet the following criteria to be eligible for inclusion in the study:~* Patients diagnosed with neovascular AMD, DME or macular edema secondary to RVO undergoing anti-VEGF injections in both eyes.~* \> 18 years old~* Able to provide signed written consent prior to participation in any study-related procedures.~Exclusion Criteria: A patient who meets any of the following criteria will be excluded from the study:~* Prescription and OTC ophthalmic mast cell stabilizers and antihistamines within 21 days prior to Screening and throughout the study period (systemic mast cell stabilizers are allowed, and systemic antihistamines are permitted)~* Use of any topical prescription ophthalmic medications (including cyclosporine \[Restasis®, Cequa®\] or topical lifitegrast \[Xiidra®\], steroids, nonsteroidal anti- inflammatory drugs \[NSAIDs\]within 7 days or during study period~* Participation in any drug or device clinical investigation within 30 days prior to study entry and/or during the study period.~* Anterior chamber cells present at time of enrollment~* History of cauterization of the punctum~* Any punctum inflammation or dacryocystitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dextenza (Type: EXPERIMENTAL): Dextenza (Dexamethasone Ophthalmic Insert 0.4 mg)
- Topical Corticosteroids (Type: ACTIVE_COMPARATOR): Topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Supplementation in CAD and Postchallenge Hyperglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 40-75~* Postchallenge hyperglycemia (2h-whole blood glucose value in oral glucose tolerance test above 119 mg/dl, normal fasting glucose)~* Angiographically verified coronary artery disease (\>50% stenosis)~* Serum 25-OH- vitamin D \< 20 ng/ml in winter/spring/autumn and \<25 ng/ml during june-september~* Stable antihypertensive therapy in the last 3 month~Exclusion Criteria:~* Acute coronary syndrome or cerebrovascular event within the previous 1 month~* BMI \> 40 kg/m²~* Serum creatinine \>2.5 times the upper limit of normal~* GOT or GPT \> 3 times the upper limit of normal~* Heart failure \> NYHA class II~* Uncontrolled hypertension (\>160/100 mmHg)~* New onset of statins, ACE-inhibitors or ARBs within the previous 4 weeks~* History of urolithiasis~* Hypercalcaemia~* Major psychiatric disorders~* Ongoing treatment with spironolactone, canrenoate, eplerenone, amiloride, triamterene and aliskiren.~* Treatment with antipsychotic drugs~* Regular significant antioxidants, vitamins or protein supplementation~* Immunosuppressive therapy~* Glucocorticoid therapy~* Ongoing chemotherapy~* Pregnancy~* Any other disease with an estimated life expectancy below 1 year.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- vitamin D (Oleovit®) (Type: ACTIVE_COMPARATOR): vitamin D drops
- Placebo (Type: PLACEBO_COMPARATOR): placebo drops

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients fulfilled the 1997 ACR modified or SLICC classification criteria of SLE；~2. New onset thrombocytopenia: platelet count \<30X109/L(by both routine test and citric acid anti-coagulated blood count test) within 3 months~Exclusion Criteria:~1. Thrombocytopenia caused by other reasons, including drugs；~2. Positive for active HAV(hepatitis A virus)/HBV(hepatitis B virus) infection~3. Active HIV(human immunodeficiency virus) or HCV(hepatitis C virus) infection;~4. Active HP(Helicopter pylori) infection;~5. Severe liver and kidney dysfunction；~6. Severe neuropsychiatric lupus；~7. No response to high dose steroid and/or cyclophosphamide 1 month prior to study enrollment；~8. Uncontrolled diabetes or hypertension before entry~9. Active GI bleeding 3 months before entry~10. Intolerant to HCQ in the past treatment history；~11. Severe bone marrow suppression or liver damage caused by cyclophosphamide in the past history；~12. Active infection , including bacteria, virus, fungi, mycobacteria~13. Allergy to any of the study medications~14. Confirmed TTP(thrombolic thrombocytopenic purpura)or CAPS(catastrophic anti-phosphilipid syndrome)~15. Platelet count less than 20X109/L with active bleeding~16. Myelodysplastic diseases~17. Patients with heart and lung function impairment~18. thiopurine S-methyltransferase (TPMT) gene positive -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Group1:Hydroxychloroquine (Type: ACTIVE_COMPARATOR): Hydroxychloroquine: 100 mg tablets by mouth, 400mg everyday for 12 months Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months
- Group 2:Cyclophosphamide (Type: ACTIVE_COMPARATOR): Cyclophosphamide, Azathioprine \& Methylprednisolone Cyclophosphamide: 200mg powder intravenous infusion, 1000mg every month for 6 month.~Azathioprine: 100 mg tablets by mouth, everyday for 6 months. Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues